Opexa Therapeutics:

Precision Immunotherapy™

Tcelna®:

Personalized T-cell immunotherapy

Abili-T:

A phase II clinical study for patients with Secondary Progressive Multiple Sclerosis

NASDAQ: OPXA: $ 0.52
CHANGE: +0.13CHANGE: +34.81% Volume: 11,945,005 May 27, 2015

World MS Day

May 27, 2015

World MS Day was launched in 2009 and brings the global Multiple Sclerosis community together to share stories, raise awareness and campaign with everyone affected by multiple sclerosis. World MS Day is the only global awareness raising campaign for MS. Every year, the MS movement comes together to provide the public with information about MS and to raise awareness on how it affects the lives of more than 2.3 million people around the world.

The MS movement is all the organizations, healthcare professionals, institutions and people affected by MS, who are working to create a world free from MS, and to make life better for people with MS in the meantime. World MS Day was established by the MS International Federation (http://www.msif.org/) and its member MS organizations for any individual, group or organization to work together to raise awareness of MS. All over the world, people are working hard to create a world without MS and to improve the lives of people affected by MS. World MS Day showcases some of that work and celebrates global solidarity and hope for the future.

Opexa would like to take this opportunity to thank the patients participating in our Abili-T clinical trial for Secondary Progressive MS, as well as their families.

Corporate Overview

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publically traded biotechnology company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. 

Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders.

MORE INFORMATION

Tcelna® (imilecleucel-T) is an autologous T-cell immunotherapy being developed for the treatment of Multiple Sclerosis (MS), and is specifically tailored to each patient's immune response profile to myelin.
OPX-212 is an autologous T-cell immunotherapy being developed for the treatment of Neuromyelitis Optica (NMO). OPX-212 is specifically tailored to each patient’s immune response to aquaporin-4.
MORE MORE

DateScript